Differential expression of carbohydrate antigen 19‑9 in human colorectal cancer: A comparison with colon and rectal cancers

Zhang,Shuai; Chen,Yijun; Zhu,Zhanmeng; Ding,Yunlong; Ren,Shuangyi; Zuo,Yunfei

doi:10.3892/mco.2013.173

Differential expression of carbohydrate antigen 19‑9 in human colorectal cancer: A comparison with colon and rectal cancers

Authors:
- Shuai Zhang
- Yijun Chen
- Zhanmeng Zhu
- Yunlong Ding
- Shuangyi Ren
- Yunfei Zuo
View Affiliations

Affiliations: Department of General Surgery, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116023, P.R. China, Department of Clinical Biochemistry, Dalian Medical University, Dalian, Liaoning 116044, P.R. China
Published online on: August 29, 2013 https://doi.org/10.3892/mco.2013.173
Pages: 1072-1078

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colorectal cancer is one of the leading causes of cancer‑related mortality, being the third most commonly diagnosed cancer among men and the second among women. Accumulating evidence regarding carbohydrate antigen (CA) demonstrated that tumor‑associated antigens are clinically useful for the diagnosis, staging and monitoring of human gastrointestinal cancers, particularly colorectal cancer. There has been an extensive investigation for sensitive and specific markers of this disease. Currently, the gastrointestinal cancer‑associated carbohydrate antigen 19‑9 (CA19‑9) is the most widely applied tumor marker in cancer diagnosis. Despite a similar etiology and cancer incidence rates, there are anatomical and clinical differences between colon and rectal cancer, as well as differences regarding tumor progression and adjuvant treatments. To investigate whether CA19‑9 is differentially expressed between colon and rectal cancer, we conducted a differential analysis of serum CA19‑9 levels among 227 cases of colorectal cancer, analyzing gender, age, Dukes' stage and distant metastasis for human colon and rectal cancer as a single entity, separately and as matched pairs. We demonstrated that the serum CA19‑9 levels in colorectal cancer were upregulated in advanced stages with distant metastasis. By contrast, the serum CA19‑9 levels in colon cancer displayed a differential and upregulated behavior in advanced stages with distant metastasis. By analyzing as matched pairs, the upregulated serum CA19‑9 levels in rectal cancer during the early stages without distant metastasis further supported our hypothesis that the expression of CA19‑9 displays a site‑specific differential behavior. The integrative analysis suggested a significant difference between human colon and rectal cancer, justifying individualized therapy for these two types of cancer.

View Figures

View References

1.	Weitz J, Koch M, Debus J, Höhler T, Galle PR and Büchler MW: Colorectal cancer. Lancet. 365:153–165. 2005. View Article : Google Scholar
2.	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
3.	Ludwig JA and Weinstein JN: Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer. 5:845–856. 2005. View Article : Google Scholar : PubMed/NCBI
4.	Chan CC, Fan CW, Kuo YB, Chen YH, Chang PY, Chen KT, Hung RP and Chan EC: Multiple serological biomarkers for colorectal cancer detection. Int J Cancer. 126:1683–1690. 2010.PubMed/NCBI
5.	Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D and Fuhrer P: Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet. 5:957–971. 1979. View Article : Google Scholar : PubMed/NCBI
6.	Goonetilleke KS and Siriwardena AK: Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 33:266–270. 2007. View Article : Google Scholar : PubMed/NCBI
7.	Yakabe T, Nakafusa Y, Sumi K, Miyoshi A, Kitajima Y, Sato S, Noshiro H and Miyazaki K: Clinical significance of CEA and CA19-9 in postoperative follow-up of colorectal cancer. Ann Surg Oncol. 17:2349–2356. 2010. View Article : Google Scholar : PubMed/NCBI
8.	Bast RC Jr, Ravdin P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM, Kemeny N, Locker GY, Mennel RG and Somerfield MR; American Society of Clinical Oncology Tumor Markers Expert Panel: 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 19:1865–1878. 2001.PubMed/NCBI
9.	Duffy MJ, van Dalen A, Haglund C, Hansson L, Klapdor R, Lamerz R, Nilsson O, Sturgeon C and Topolcan O: Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer. 39:718–727. 2003. View Article : Google Scholar : PubMed/NCBI
10.	Gupta MK, Arciaga R, Bocci L, Tubbs R, Bukowski R and Deodhar SD: Measurement of a monoclonal-antibody-defined antigen (CA19-9) in the sera of patients with malignant and nonmalignant diseases. Comparison with carcinoembryonic antigen. Cancer. 56:277–283. 1985. View Article : Google Scholar : PubMed/NCBI
11.	Thomas WM, Robertson JF, Price MR and Hardcastle JD: Failure of CA19-9 to detect asymptomatic colorectal carcinoma. Br J Cancer. 63:975–976. 1991. View Article : Google Scholar : PubMed/NCBI
12.	Iemura K and Moriya Y: A comparative analysis of the serum levels of NCC-ST-439, CEA and CA19-9 in patients with colorectal carcinoma. Eur J Surg Oncol. 19:439–442. 1993.PubMed/NCBI
13.	Tan KK, Lopes Gde L Jr and Sim R: How uncommon are isolated lung metastases in colorectal cancer? A review from database of 754 patients over 4 years. J Gastrointest Surg. 13:642–648. 2009.PubMed/NCBI
14.	Iacopetta B: Are there two sides to colorectal cancer? Int J Cancer. 101:403–408. 2002. View Article : Google Scholar : PubMed/NCBI
15.	Fearon ER: Molecular genetics of colorectal cancer. Annu Rev Pathol. 6:479–507. 2011. View Article : Google Scholar : PubMed/NCBI
16.	Kapiteijn E, Liefers GJ, Los LC, Kranenbarg EK, Hermans J, Tollenaar RA, Moriya Y, van de Velde CJ and van Krieken JH: Mechanisms of oncogenesis in colon versus rectal cancer. J Pathol. 195:171–178. 2001. View Article : Google Scholar : PubMed/NCBI
17.	Weissenberger C, Von Plehn G, Otto F, Barke A, Momm F and Geissler M: Adjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: role of CEA and CA 19-9. Anticancer Res. 25:1787–1793. 2005.PubMed/NCBI
18.	Hinoue T, Weisenberger DJ, Lange CP, Shen H, Byun HM, Van Den Berg D, Malik S, Pan F, Noushmehr H, van Dijk CM, Tollenaar RA and Laird PW: Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res. 22:271–282. 2012. View Article : Google Scholar : PubMed/NCBI
19.	Birkenkamp-Demtroder K, Olesen SH, Sørensen FB, Laurberg S, Laiho P, Aaltonen LA and Ørntoft TF: Differential gene expression in colon cancer of the caecum versus the sigmoid and rectosigmoid. Gut. 54:374–384. 2005. View Article : Google Scholar : PubMed/NCBI
20.	Cui H, Cruz-Correa M, Giardiello FM, Hutcheon DF, Kafonek DR, Brandenburg S, Wu Y, He X, Powe NR and Feinberg AP: Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science. 299:1753–1755. 2003. View Article : Google Scholar : PubMed/NCBI
21.	Jorissen RN, Gibbs P, Christie M, Prakash S, Lipton L, Desai J, Kerr D, Aaltonen LA, Arango D, Kruhøffer M, Orntoft TF, Andersen CL, Gruidl M, Kamath VP, Eschrich S, Yeatman TJ and Sieber OM: Metastasis-associated gene expression changes predict poor outcomes in patients with Dukes stage B and C colorectal cancer. Clin Cancer Res. 15:7642–7651. 2009. View Article : Google Scholar
22.	Dunican DS, McWilliam P, Tighe O, Parle-McDermott A and Croke DT: Gene expression differences between the microsatellite instability (MIN) and chromosomal instability (CIN) phenotypes in colorectal cancer revealed by high-density cDNA array hybridization. Oncogene. 21:3253–3257. 2002. View Article : Google Scholar
23.	Ahlquist DA, Skoletsky JE, Boynton KA, Harrington JJ, Mahoney DW, Pierceall WE, Thibodeau SN and Shuber AP: Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology. 119:1219–1227. 2000. View Article : Google Scholar : PubMed/NCBI
24.	Frattini M, Balestra D, Pilotti S, Bertario L and Pierotti MA: Tumor location and detection of k-ras mutations in stool from colorectal cancer patients. J Natl Cancer Inst. 95:72–73. 2003. View Article : Google Scholar : PubMed/NCBI
25.	Li FY and Lai MD: Colorectal cancer, one entity or three. J Zhejiang Univ Sci B. 10:219–229. 2009. View Article : Google Scholar : PubMed/NCBI
26.	Sanz-Pamplona R, Cordero D, Berenguer A, Lejbkowicz F, Rennert H, Salazar R, Biondo S, Sanjuan X, Pujana MA, Rozek L, Giordano TJ, Ben-Izhak O, Cohen HI, Trougouboff P, Bejhar J, Sova Y, Rennert G, Gruber SB and Moreno V: Gene expression differences between colon and rectum tumors. Clin Cancer Res. 17:7303–7312. 2011. View Article : Google Scholar : PubMed/NCBI
27.	Wang WS, Lin JK, Chiou TJ, Liu JH, Fan FS, Yen CC, Lin TC, Jiang JK, Yang SH, Wang HS and Chen PM: CA19-9 as the most significant prognostic indicator of metastatic colorectal cancer. Hepatogastroenterology. 49:160–164. 2002.PubMed/NCBI